NCT03548584: A trial that was reported late by Otsuka Pharmaceutical Development & Commercialization, Inc.
This trial has reported, although it was 8 days late in doing so.
Full data
| Full entry on ClinicalTrials.gov | NCT03548584 |
|---|---|
| Title | A Phase 3, 12-Week, Multicenter, Randomized, Double-blind, Placebo-controlled, 2-Arm, Fixed-dose Trial to Evaluate the Efficacy, Safety, and Tolerability of Brexpiprazole (OPC-34712) in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimer's Type |
| Results Status | Reported (late) |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | May 16, 2018 |
| Completion date | May 23, 2022 |
| Required reporting date | May 23, 2023, midnight |
| Actual reporting date | May 31, 2023 |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | 8 |